Patients taking Invokana® are reporting the development of ketoacidosis. If you have experienced serious side effects, you may want to consider finding a helpful Invokana lawsuit lawyer at the Hollis Law Firm today!
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a newer type of drug designed to help patients suffering from Type 2 diabetes manage their blood glucose levels. These inhibitors work by stopping sugar from being reabsorbed back into the body while passing through the kidneys. The kidneys then release the sugar into the bladder so the body can secrete it during urination. One of the more popular SGLT2 inhibitors is a creation from Johnson & Johnson called Invokana. Other SGLT2 inhibitors include Farxiga®, Xigduo®, Jardiance®, and Glyxambi®. In May of 2015, the FDA issued a safety warning about Invokana and the other SGLT2 inhibitors stating that patients were reporting that they had developed serious cases of ketoacidosis after taking Invokana and other SGLT2 inhibitors. As a result, many are seeking a knowledgeable Invokana lawsuit lawyer at the Hollis Law Firm.
In the safety warning, the FDA stated that “these type 2 diabetes medicines may lead to ketoacidosis…” Ketoacidosis is a serious condition where the patients may fall into a diabetic coma due to dangerously low blood sugar. In addition to ketoacidosis, other symptoms related to complications from Invokana use are:
- Difficulty breathing
- Nausea or vomiting
- Abdominal pain
- Confusion and dizziness
The knowledgeable Invokana lawsuit lawyer at the Hollis Law Firm frequently represent those who have fallen victim to a harmful drugs. An experienced Invokana lawsuit lawyer can help you determine if your case is a viable claim against the manufacturers of Invokana, Johnson & Johnson. Contact the Hollis Law Firm’s compassionate Invokana side effect attorneys by filling out the form on this page or calling 1-800-701-3672 today. The Hollis Law Firm has experience representing clients across the United States. Call now for a free Invokana lawsuit review.